Login to Your Account



Acacia delivers positive phase III readout for PONV candidate

By Nuala Moran
Staff Writer

Monday, October 6, 2014
In one of the things you seldom see in UK biotech, Acacia Pharma Ltd. has delivered positive phase III results for ADP421 in postoperative nausea and vomiting, and embarked on planning the route to commercialization in the U.S.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription